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Summary The development of antioestrogen resistance is a major clinical obstacle encountered in the
treatment of breast cancer. By long-term growth in oestrogen-free medium, we have derived an oestrogen-
independent, anti-oestrogen resistant cell line from the oestrogen receptor (ER)-positive, oestrogen-dependent
T47D human breast cancer cell line. This cell line grows maximally in oestrogen-free medium and is resistant to
all tested antioestrogens. This cell line does not express any measurable amounts of ER mRNA or protein and,
in short-term studies, these cells show no response to either oestrogens or antioestrogens. However, return of
these cells to oestrogen-containing medium for more than 8 weeks resulted in the re-expression of ER mRNA
and protein. Subsequent limiting dilution subcloning of the T47D:C4 line revealed two phenotypically distinct
clones, one which did not express measurable ER after long-term growth in oestrogen-containing medium and
one which expressed ER mRNA and protein after a number of weeks in oestrogen-containing medium. In the
absence of oestrogen, both types of cells are ER-negative as determined by Northern and Western blotting and
lack of any oestrogen-dependent responses. The clone which re-expresses the ER (T47D:C4:5W) now responds
to E2 with a 50% increase in growth and a 30-fold induction of an ER-reponsive luciferase reporter construct.
Long-term growth of the stably ER-negative clone (T47D:C4:2W) causes no measurable oestrogen-mediated
responses, as assessed by ER expression, growth stimulation or luciferase induction. Interestingly, ER mRNA
can be detected in both cell types by using reverse transcriptase-polymerase chain reaction (RT-PCR). This
suggests that the ER mRNA present in the T47D:C4:2W clone is either inefficiently translated or is present at
such a low level as to be functionally irrelevant. These novel clonal cell lines will prove to be invaluable in the
study of the regulation of ER expression and regulatory pathways leading to oestrogen-independent growth.
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The hormonal dependence of breast cancer has been known
since the studies of Beatson in the late nineteenth and Boyd
in the early twentieth century (Beatson, 1896; Boyd, 1900). In
these studies ovariectomy was shown to inhibit the growth of
advanced breast cancers. The development of in vitro breast
cancer models was pioneered by Soule (Brooks et al., 1973;
Soule et al., 1973), but the finding that the cells would
respond to oestrogens and antioestrogens by Lippman (1976)
allowed the investigation of oestrogenic growth stimulation in
this particular target tissue.
The clinical response of human breast cancer to endocrine
therapy is dependent upon a functional oestrogen receptor
(ER). At diagnosis nearly 70% of all primary breast cancers
express measurable levels of the ER and, of these, 50% also
express progesterone receptor (PR) (Paridaens, 1995). The
expression of PR has been shown to be dependent upon an
activated ER complex and, therefore, PR expression is used
as a measure of the activity of the ER present in these
tumours. It has been shown that the use of ER and PR
expression is invaluable as a prognostic indicator for
antioestrogen response (Clark et al., 1984). Tumours with
neither ER nor PR show less than a 10% response to any
hormonal manipulation, including the non-steroidal antioes-
trogen tamoxifen, which is currently the hormonal treatment
of choice for breast cancer (Jordan, 1994). However, nearly
80% of tumours expressing ER and PR will show an
objective response to hormonal manipulation. Unfortunately,
following an initial response, nearly all advanced breast
cancers will develop resistance to this treatment. The changes
that allow these resistant cells to develop and eventually lead
to disease progression are multifaceted and largely unknown.
Loss of oestrogen dependence is not always a precursor to
the development of antioestrogen resistance. However, these
two characteristics are theorectically and observationally
linked. The expression of ER in tumours as they progress
has recently been reviewed by Robertson (1996). In this
review, the loss of ER expression in previously ER-positive
tumours is seriously questioned. The hypothesis that ER
expression is stable in breast cancer has significant
consequences in the treatment of breast cancer. Many
laboratories (Brunner et al., 1993; Clarke et al., 1989;
Dickson and Lippman, 1986; Katzenellenbogen et al., 1987;
Wilding et al., 1988) including our own (Jiang et al., 1992;
Murphy et al., 1989; Pink et al., 1995; Robinson and Jordan,
1989; Welshons and Jordan, 1987) have used cell culture
models of human breast cancer to study the development of
oetrogen independence and antioestrogen resistance.
The discovery of the oestrogenic activity of the pH
indicator, phenol red, and its removal from tissue culture
medium (Berthois et al., 1986), allowed us, as well as other
laboratories, to analyse the changes in breast cancer growth
in long- and short-term oestrogen deprivation studies.
Previously, we described two clones derived from the MCF-
7 human breast cancer cell line, which were selected in
oestrogen-free medium. Both of these clones grow maximally
in oestrogen-free medium and continue to express the ER.
One clone, MCF-7:5C, is oestrogen and antioestrogen
resistant in all measured responses (Jiang et al., 1992). The
growth of the other clone, MCF-7:2A, is also oestrogen
independent, but can be dramatically inhibited by antioestro-
gens. This cell line also expresses a unique 80 kilodalton
(kDa) ER which contains an in-frame duplication of exons 6
and 7 (Pink et al., 1995, 1996).
In parallel studies we examined the development of
oestrogen independence in the T47D cell line (Murphy et
al., 1989, 1990). This cell line has been well studied in
numerous laboratories throughout the world. The initial
characterisation of this cell line established that it was ER
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and PR positive and required oestrogen for maximal growth
(Chalbos et al., 1982; Keydar et al., 1979). Interestingly,
independently maintained clones used in various laboratories
now show a diversity of phenotypes (Fernandez et al., 1994;
Graham et al., 1990; Horwitz and Freidenberg, 1985; Karey
and Sirbasku, 1988; Mullick and Chambon, 1990; Murphy et
al., 1989; Nardulli and Katzenellenbogen, 1988; Reese et al.,
1988; Wang and Miksicek, 1991).
In studies described here we investigate the characteristic
of two T47D clones, which have lost their oestrogen
responsiveness following growth in oestrogen-depleted
medium. These clones and the parental oestrogen-responsive
cell line, T47D:A18, will be excellent models in which to
investigate the changes associated with the development of
oestrogen independence and the subsequent re-expression of
the ER in human breast cancer.
Materials and methods
Tissue culture
T47D cells were originally obtained from the American Type
Culture Collection (ATCC), Rockville, MD, USA). All tissue
culture components were purchased from Gibco Laborator-
iers, Grand Island, NY, USA, unless otherwise stated. Cells
were grown in RPMI-1640 supplemented with 10% fetal
bovine serum (FBS; Bioproducts for Science Inc., Indiana-
polis, IN, USA), 6 ng ml-' bovine insulin, 25 mM Hepes,
2 mM L-glutamine, 100 U ml-' penicillin, 100 ,ug ml-1
streptomycin and 250 ng ml-' amphotericin B (fully oestro-
genised medium). Oestrogen-free medium substitutes phenol-
red free RPMI-1640 and 3 x dextran-coated charcoal-treated
FBS in the above. Cells were routinely passed at 1: 5- 1: 20
dilutions once per week using 0.1% trypsin. All cells were
grown in a 37°C humidified incubator with 5% carbon
dioxide. Derivation of the T47D:A18 and T47D:C4 lines has
been described previously (Murphy et al., 1989, 1990).
Limiting dilution cloning was performed by diluting cells
to 25 cells per 200 Ml medium and seeding 200 Ml into the first
row of a 96-well plate. Using an 8 channel micropipettor
(Oxford Labware, St Louis, MO, USA), 100 pl of this
solution was then added to 100 pl of medium in the second
row with mixing; these 1: 2 dilutions were then repeated for
the remaining rows. After 2 weeks all wells were inspected
under low magnification and wells containing single colonies
were noted and harvested approximately 3 weeks later.
Growth assays
All cells were grown in oestrogen-free medium for at least 2
days before the beginning of each experiment. Cells were
seeded into each well of a 24-well plate (20 000 cells per well)
in 1 ml of oestrogen-free medium on day 0. The following
day (day 1) this medium was removed and 1 ml of medium
containing the appropriate compound(s) was added. All
compounds were dissolved in 100% ethanol and added to
the medium at a 1: 1000 dilution. Medium was changed on
day 4 and experiments were ended on day 6. For time course
experiments cells were harvested daily and medium was
changed on days 4 and 6. DNA content was determined by
the method of LaBarca and Paigen (1980), using a
fluorocolorimeter II (SLM Aminco Urbana, IL, USA). 17fl-
Oestradiol was purchased from Sigma Chemical, 4-hydro-
xytamoxifen was a generous gift from Zeneca Pharmaceu-
ticals (Macclesfield, UK) and ICI 164,384 was a generous gift
from Alan Wakeling, Zeneca Pharmaceuticals.
Western blotting
Western blotting was performed as described previously (Pink
and Jordan, 1996). Briefly, whole cell extracts were prepared
by direct lysis of phosphate-buffered saline (PBS) washed
cells in sample buffer (10% glycerol, 150 mM Tris-HCl
pH 6.8, 0.5 mM EDTA, 0.125% sodium dodecyl sulphate
(SDS), 1% ,B-mercaptoethanol and 5 pg ml-1 bromophenol
blue) followed by immersion in a boiling water bath for 5-
10 min. Following electrophoresis, proteins were transferred
to Hybond-C (Amersham Corp., Arlington Heights, IL,
USA) and the membrane was incubated with a 1: 500
dilution of antibody in 10% calf serum, 1 x PBST for 2 h
at 20°C wth gentle shaking. The rat anti-human ER
antibody, H222, was a generous gift from Abbott
Laboratories. The horseradish peroxidase-conjugated goat
anti-rat IgG secondary antibody (Hyclone Laboratories Inc.,
Logan, UT, USA) was diluted 1: 10 000 in 1 x PBST plus
10% calf serum and incubated with the membrane for 2 h at
20°C with gentle shaking. Following washes, the proteins of
interest were visualised by incubation with ECL reagent
(Amersham Corp) as per the manufacturer's directions.
Radiogaphic film was exposed to the membranes for 0.5-
30 min in a standard autoradiography cassette at room
temperature.
Transient transfection assays
Cells were seeded into a 6-well plate (500 000 cells per well)
in phenol red-free RPMI plus 10% 3 x charcoal-stripped
FBS. The following day medium was removed and replaced
with fresh oestrogen-free medium. A solution containing 1 Mg
of the luciferase reporter construct, pVIT3-luc (Pink et al.,
1995), and 0.5 Mg of the ,B-galactosidase receptor, pCMV,B
(MacGregor and Caskey, 1989), in 0.25 M calcium chloride
was mixed dropwise with an equal volume of 2 x HBS
(0.28 M sodium chloride, 0.05 M Hepes, 1.5 mM sodium
phosphate, pH 7.05) by gently bubbling air through the
solutions. This solution was then incubated at room
temperature for 20 min to allow a DNA/calcium phosphate
precipitate to form. An aliquot of 0.4 ml of this solution was
slowly added to the cells in 3.6 ml medium and incubated at
37°C in a humidified incubator with 5% carbon dioxide for
6 h. At that time the DNA solution was removed and the
cells were shocked with a solution of 10% glycerol in 1 x
HBS for 3 min. This solution was then removed and the cells
washed twice with 4 ml PBS. Medium with or without
compounds was then added to the wells and incubated at
37°C in a humidified 5% carbon dioxide incubator for an
additional 42 h. The medium was then removed and the cells
were washed once with ice-cold PBS. The cells were then
scraped in extraction buffer [potassium hydrogen phosphate,
pH 7.5, 1% Triton X-100, 100 Mg ml-' bovine serum
albumin (BSA), 2.5 mM phenylmethylsulphonly fluoride
(PMSF) and 1 mm dithiothreitol (DTT)] and pipetted
vigorously to ensure complete cell lysis. Debris was then
pelleted by spinning in a microfuge for 1 min and the lysate
was stored on ice until luciferase activity was assayed.
Luciferase activity was assayed by mixing 50,l of each
lysate with 350 ,l of reaction buffer (160 mM magnesium
chloride, 75 mM glycylglycine pH 7.8, 0.5 mg ml-' BSA,
19 mg ml-1 ATP and 15 mM Tris-HCl, pH 7.5). To begin
each assay 100 ,l of substrate (0.4 mg ml-1 luciferin
potassium salt in 10 mM sodium carbonate, pH 6.0) was
automatically injected into the lysate mixture. Each point was
monitored for 10 s by a Monolight 2010B luminometer
(Analytical Luminescence Laboratory, San Diego, CA, USA)
and RLU was then reported. All points were corrected for
transfection efficiency by dividing RLU by /3-galactosidase
activity.
/3-Galactosidase activity was measured using a MUG assay
(Luyten et al., 1985). Briefly, an aliquot of the cell is mixed
with 1.3 ml reaction buffer containing 0.1 M sodium
phosphate, 10 mM potassim chloride, 1 mM magnesium
sulphate, pH 7.0 and 2.2 (10-5)g ml-'1B-methyllumbellifer-
one (MUG) (Molecular Probes Inc., Eugene, OR, USA). The
sample is incubated at room temperature for 1 h and 750 Ml
of stop buffer (15 mM EDTA, 0.3 M glycine, pH 11.2) is
added. The samplcs are then read in an LS-5 fluorescence
spectrophotometer (Perkin Elmer, Foster City, CA, USA)
with excitation at 350 nm and absorption at 450 nm. AllOestrogen receptor expression in T47D cell lines
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samples are correlated to a standard curve using purified f,-
galactosidase (Boehringer Mannheim Biochemicals, Indiana-
polis, IN, USA).
Northern and RNA dot-blot analysis
RNA was isolated from two 100 cm2 dishes using a
procedure of direct poly A RNA purification (Badley et al.,
1988). Briefly, the cells were washed twice in ice-cold PBS
containing 50 gM ATA and then lysed in a solution of 0.2 M
sodium chloride, 0.2 M Tris-HCl, pH 7.5, 1.5 mM magnesium
chloride, 2% SDS, 200 Mg ml-' proteinase K and 50 pM
aurin tricarboxylic acid (ATA). Following shearing of the
DNA through a 22 g needle five times, the lysate is mixed
with oligo-dT cellulose for 2 h at room temperature. The
oligo-dT pellet is then washed four times with binding buffer
(0.5 M sodium chloride, 0.01 M Tris-HCl, pH 7.5) by
spinning at 500 xg in a Beckman J6-B centrifuge at room
temperature. The RNA is eluted in five batches by
resuspending the oligo-dT pellet in elution buffer (0.01 M
Tris-HCl, pH 7.5) and spinning at top speed in a microfuge
for 30 s. The RNA was denatured by heating to 65°C for
15 min in 10 mM MOPS, pH 7.0, 4 mM sodium acetate,
0.5 mM EDTA, 6.5% formaldehyde and 50% deionised
formamide. For Northern blots the denatured RNA was
loaded onto a 1.2% agarose/formaldehyde gel and run
overnight at 25V with buffer recirculation. Transfer was
performed using a Vacu-Gene transfer apparatus (Pharmacia
Biotech Inc., Piscataway, NJ, USA) according to the
manufacturer's directions. For dot-blots the dilutions were
then spotted onto Hybond-N (Amersham) using a Hybri-Dot
manifold (BRL, Gaithersburg, MD, USA), 0.5-20 Mg RNA
per well and each well was rinsed under low vacuum once
with 400 Ml 10 x saline sodium citrate (SSC). The membranes
for both dot-blots and Northern blots were then UV fixed
using a UV Stratalinker 2400 (Stratagene, La Jolla, CA,
USA) and air dried before prehybridisation. Prehybridisation
was performed at 45°C using a solution comprised of 5 x
SSC, 20 mm sodium phosphate, pH 6.5, 0.6% polyvinylpyr-
rolidone, 0.1% Ficoll, 0.1% BSA, 0.2% SDS, 250 Mg ml-'
denatured salmon sperm DNA, 50% deionised formamide
and 10% sodium dextran sulphate. The DNA probes were
prepared by random primer labelling using Klenow poly-
merase (Promega, Madison, WI, USA). Hybridisation was
carried out by adding 2-4 x 107 d.p.m. ml-' ofthe denatured
probes directly to the prehybridisation buffer and incubating
for 12-16 h at 45°C. The membranes were then washed in
2 x SSC, 0.2% SDS at room temperature for 2-3 h with
four buffer changes, followed by one wash in 0.1 x SSC,
0.2% SDS at 65°C for 15 min. The membranes were then
exposed to Kodak X-OMAT film in an autoradiography
cassette containing double Quanta III intensifying screens at
-700C for 24-200 h.
Single-strand conformational polymorphism (SSCP) analysis
Total RNA (5 Mg) was reverse transcribed in a 20 pM reaction
containing 50 mM Tris-HCl, pH 8.4, 125 mM potassium
chloride, 6.25 mM magnesium chloride, 10 mM dithiothrei-
tol, 3 gM oligo-dT(12 18) primer, 0.5 mM each dATP, dCTP,
dGTP, dTTP, 2.0 units E. coli RNAase H and 100 units
Superscript reverse transcriptase (Gibco BRL). PCR ampli-
fication and 32p labelling were performed in 50 Ml reactions
containing 10 mM Tris-HCl, 50 mM potassium chloride,
1.5 mM magnesium chloride, 0.2 mM each dATP, dCTP,
dGTP, dTTP, 2.5 U AmpliTaq DNA polymerase (Perkin
Elmer, Norwalk, CT, USA) and 0.1 gM each of two primers
(one upstream and one downstream for primer sets U2/D2,
U3/D3, U4/D4 and U5/D5). Amplification of the region
encompassed by primers U1/D1 could not be amplified by
the above method secondary to the high GC content (65%)
of this region. For U1/D1 amplification a 50 Ml reaction
containing 6 mM Tris-HCl, pH 8.0, 30 mM potassium
chloride, 1.1 mM magnesium acetate, 0.1 mM dithiothreitol,
0.25 mM each dATP, dCTP, dGTP, dTTP, 2 units rTth DNA
polymerase (Perkin Elmer), and 0.1 gM of each U1 and D,
primers. In addition, 5 mCi each of [32P]dATP and [32P]dCTP
were added to each PCR reaction (Amersham).
Amplification was carried out (for primer sets U2/D2, U3/
D3, U4/D4 and U5/D5) for 30 cycles at 94°C for 15 s, 60°C for
15 s and 72°C for 15 s. The final extension was carried out at
72°C for 5 min. For primer set U,/Di amplification was
carried out for 30 cycles at 94°C for 15 s and 650C for
10 min. The final extension was carried out at 72°C for
12 min.
The cDNA was amplified in five separate overlapping
regions as previously described (Wolf and Jordan, 1994) and
shown in Figure 9b. After amplification the resultant 32p_
labelled DNA underwent restriction enzyme digest with the
enzyme appropriate for each primer pair. After digestion the
radiolabelled DNA was diluted 1:4 with 0.1% SDS, 10 mM
EDTA. This sample was then diluted 1:1 with a denaturing
loading buffer containing 95% formamide, 20 mm EDTA,
0.05% bromophenol blue and 0.05% xylene cyanol. The
samples were heated at 90°C for 5 min before loading onto a
5% acrylamide gel containing 0.5 x Tris-borate/EDTA
(45 mM Tris-HCl, 45 mM boric acid, 2 mM EDTA, pH 8.3)
and 5% glycerol. Electrophoresis was run at room
temperature at a constant power of 16 W. Gels were dried
in a vacuum gel dryer at 80°C for 1 h. Dried gels were
exposed to radiograhic film (Hyperfilm-MP, Amersham) at
room temperature for 14- 16 h.
Results
Derivation of the ER-negative clones
In previous studies, we demonstrated that the T47D:C4 cell
line was refractory to oestrogen and antioestrogen in short-
term (<2 weeks) studies (Murphy et al., 1990). To study the
long-term effects of oestrogens on the T47D:C4 cells, we
cultured these cells in medium containing whole serum and
phenol red. After 16 weeks, RNA was prepared from
T47D:C4 cells grown in oestrogen-free or oestrogen-contain-
ing medium. The ER-positive T47D:A18 cell line was
included as a positive control and the MDA-MB-231 cell
line as a negative control. A Northern blot was performed
using 10 Mg of poly-A+-enriched RNA per group and probed
with a 32P-labelled human ER cDNA. As seen in Figure 1,
the T47D:A18 cells express high levels of the 6.2 kb ER
mRNA and the T47D:C4 and MDA cells do not visibly
express any ER mRNA. Interestingly, the T47D:C4 cells
grown in oestrogen-containing medium (T47D:C4WS) show
an observable ER mRNA signal nearly equal to that of the
T47D:A18 cells.
1 2 3 4
9.4 kbp --
6.5 kbp 0
4.3 kbp - *
Figure 1 Northern blot analysis of ER expression. PolyA+ RNA
(10 g) was probed with the 2P-labelled human ER cDNA. Lane
1, T47D:A18 cells grown in oestrogen-containing medium. Lane
2, T47D:C4 cells grown in oestrogen-free medium. Lane 3, MDA-
MB-231 cells grown in oestrogen-free medium. Lane 4, T47D:C4
cells grown in oestrogen-containing medium for 16 weeks. The
ER message migrates at 6.2kb, as determined from a A-HindIIl
marker.Oestrogen receptor expression in T47D cell lines
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To study the time frame ofthe ER-re-expression, T47D:C4
cells were cultured in oestrogen-containing medium and RNA
was prepared periodically. These RNA samples were probed
for ER expression using the human ER cDNA in a dot-blot.
A parallel group was cultured in oestrogen-containing
medium plus 100 nM 4-hydroxytamoxifen (4-OHT) in order
to examine the effect of antioestrogens on the ER mRNA re-
expression. In the dot-blot shown in Figure 2, it can be seen
that the ER mRNA becomes visibly expressed after
approximately 5 weeks and is nearly equal to that of the
T47D:A18 cells by 9 weeks. The presence of 4-OHT can
completely block this re-expression, even after 18 weeks in
oestrogen-containing medium. This clearly demonstrates the
involvement of the ER in this process. PR expression was
also measured in these samples and was shown to mirror the
ER expression (data not shown).
To determine if this response was caused by a global re-
expression of the ER, as opposed to the selective outgrowth
of an ER-positive subpopulation, the T47D:C4 cells were
subjected to another round of limiting dilution subcloning in
oestrogen-free medium. Nine clones were chosen for further
study and each clone was divided into two groups; one was
cultured in oestrogen-free medium and the other was
switched to medium containing whole serum and phenol
red. After 6 weeks of culture, mRNA was prepared and
analysed in Northern blot using the human ER cDNA.
0 0.5 1.0 2.0 3.0 5.0 10 20
Control
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T47D:C4
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T47D:C4
T47D:C4
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T47D:C4
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Figure 2 Time course analysis of ER mRNA expression.
T47D:C4 cells were cultured in oestrogen-containing medium at
time 0 and RNA was prepared at various intervals. RNA
dilutions were then loaded into a dot-blot at the amounts noted at
the top of the blot (jg per well). The T47D:C4 cells were also
cultured in complete medium containing 10-7M 4-OHT and RNA
was prepared at 18 weeks. This dot-blot was then hybridised with
the 32P-labelled human ER cDNA.
Figure 3 clearly shows that the T47D:C4 cells contain two
distinct subpopulations. The majority of the clones do not
express ER mRNA after 6 weeks in oestrogen-containing
medium. However, two clones T47D:C4:4 and T47D:C4:5,
showed measurable ER mRNA after 6 weeks in oestrogen-
containing medium. The designation 'W' at the end of a
clone name indicates that these cells are routinely cultured in
oestrogen-containing medium with whole serum. Loading and
transfer efficiency was determined by reprobing the blot with
a human f3-actin cDNA probe. The culture history of these
various clones is illustrated in Figure 4. One ER-positive and
one ER-negative clone were chosen for further study. The
clone, T47D:C4:2W, was selected as a permanently ER-
negative clone and the T47D:C4:5W clone was selected to
represent the originally ER-negative clone, which could re-
express the ER when cultured in oestrogen-containing medium.
The T47D:A18 clone was included in all studies as an ER-
positive oestrogen- dependent control.
ER protein expression
A number of studies were then undertaken in order to assess
the expression and activity of the ER in the clones. The
expression of the ER protein was measured in a Western blot
using the monoclonal antibody H222. All cell lines were
continuously cultured in medium containing whole serum and
phenol red in order to ensure that the T47D:C4:2W clone
was truly ER negative and would remain ER negative even
when grown in oestrogen-containing medium for prolonged
times. Before studying the effect of oestrogen on the cells,
they were grown in oestrogen-free medium for 4-6 days.
Figure 5 shows the result of a Western blot of whole cell
extracts of the clones following growth in oestrogen-free (-)
or oestrogen-containing medium (+) for 6 days. Both the
T47D:A18 and T47D:C4:5W clones express measurable ER
protein, which is decreased in the T47D:A18 cells following
growth in oestrogen-deprived medium. The T47D:C4:2W
cells, in contrast, do not express any measurable ER in either
culture medium.
Growth response
The consequence ofre-expression ofthe ER was then assessed
in a 6 day growth assay. Dose-reponse curves were generated
by measuring growth of the T47D:A18, T47D:C4:2W and
T47D:C4:5W cells in the presence ofvarying concentrations of
E2 and/or 4-OHT (Figure 6). The growth ofthe T47D:A18 cells
in oestrogen-containing medium is 6-fold higher than that of
T47D:A18 cells grown in the absence ofoestrogen (Figure 6a).
Growth ofthe T47D:A18 clone in the presence of4-OHT alone
showed a partial oestrogenic effect(approximately 50% growth
increase) (Figure 6b) and the addition of4-OHT could inhibit
the E2-stimulated growth of the T47D:A18 clone (Figure 6c).
The ER-negative T47D:C4:2W clone displays no change in
growth in any treatment group. The T47D:C4:5W clone
exhibits an intermediate phenotype with a higher basal growth
rate in control medium and an approximately 2-fold increase in
#S 0 NN N3 N N N N<NO
<4- ER
Figure 3 Northern blot of T47D:C4 subclones. Clones were derived by limiting dilution cloning and RNA was prepared from the
original clone grown in oestrogen-free medium and from cells grown for 6 weeks in oestrogen-containing medium. Poly+ RNA
(10jig) was probed with the human ER cDNA. A18 and all clones ending in 'W' were grown in oestrogen-containing medium; all
others were grown in oestrogen-free medium. See Figure 4 for a description of the derivation of these clones.
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Figure 4 Flow chart of the derivation of the T47D clones. Complete medium contains 10% whole fetal bovine serum in RPMI-
1640. Oestrogen-free medium consists of 10% 3 x charcoal-stripped fetal bovine serum in phenol red-free RPMI-1640. See
Materials and methods for a description of the cloning scheme.
growth in the presence of E2. The addition of4-OHT was able
to inhibit this growth stimulation (Figure 6c). Treatment with
4-OHT alone had no effect on the T47D:C4:5W cells until
concentrations greater than 10-6 M were achieved. At these
higherconcentrations of4-OHT, a non-ER-mediated toxicity is
observed, as demonstrated by the growth inhibition seen in all
the cells, including the T47D:C4:2W clone.
Reporter gene induction
The function of the ER was further assessed by testing the
ability of the clones to induce expression of a luciferase
reporter construct under the control of three copies of the
consensus vitellogenin A2 oestrogen response element. As
seen in Figure 7, the T47D:A18 clohe gives a dramatic
(>100-fold) dose-dependent induction of luciferase in the
presence of E2. The T47D:C4:2W clone shows no measurable
response at any concentration of E2. The T47D:C4:5W clone
demonstrates an intermediate (approximately 30-fold) in-
crease in luciferase expression in the presence of E2. The
luciferase activity in control medium is negligible in all
groups and is unchanged by the pure antioestrogen, ICI
182,780 (data not shown).
Southern blotting
The genomic structure of the ER in the clones was then
investigated using standard Southern blotting techniques.
EcoRI- and HindIII-digested genomic DNA was used to
assess any changes in the restriction pattern of the ER gene
in the threeclones. As seen in Figure 8, the pattern ofrestriction
fragments is unchanged in the three clones. These data indicate
that the E2-independent clones have not lost the ER gene or
undergone any major structural alterations of the gene.
SSCP analysis
Lastly, the structure of the ER mRNA in the clones was
analysed using oligo-dT(12 18)-primed cDNA as a substrate
for SSCP. Five primer sets, which cover the entire coding
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Figure 5 Expression of ER protein in T47D clones. Whole cell
extracts were prepared from cells grown in oestrogen-containing
(+) or oestrogen-free (-) medium for 6 days. ER was probed
with the monoclonal antibody, H222, and a goat anti-rat HRP
secondary antibody, and visualised using the ECL reagent. Equal
total protein was loaded in each lane as determined by Ponceau S
staining of the membrane.
region of the ER cDNA, were used to amplify sections of the
cDNA (Figure 9b). These products were then run on a non-
denaturing SSCP gel. Shown in Figure 9a are the results from
this analysis. MCF-7:WS8 cDNA was included as a wild-type
ER-positive control and MDA-MB-231 cDNA was included
as an ER-negative control (Pink et al., 1995). Surprisingly, all
groups, except the water control, gave rise to PCR products
in all primer sets. The presence of specific PCR products was
unexpected in the MDA-MB-231 and T47D:C4:2W groups,
as these clones do not express any measurable amounts of
ER mRNA as measured by Northern blotting, or ER protein
as measured by Western blotting. While this result was
unexpected, ER mRNA has previously been observed by
PCR in the ER-negative cell line, MDA-MB-231 (Daffada et
al., 1994). The pattern of PCR products was the same in all
groups, suggesting that the primary ER cDNA sequence in
all groups is identical.
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Discussion
The development of oestrogen-independent growth in
previously oestrogen-dependent breast cancers is a major
obstacle in the hormonal treatment of these tumours.
Expression of the ER is absolutely critical for the
maintenance of oestrogen dependence and, while the
presence of functional ER does not always correlate with
oestrogen-responsive growth, its complete absence always
correlates with a loss of oestrogen responsiveness. The clinical
relevance of the loss of the ER has recently come into
question as, described by Robertson (1996). This phenomen-
on is currently under intense investigation in the context of
the use of the new pure antioestrogens, which have been
shown to function by causing a rapid loss of the ER (Gibson
et al., 1991; Pink and Jordan, 1996). In order to investigate
the mechanisms responsible for the loss of E2 dependence and
ER expression, we have developed and studied clones of the
T47D human breast cancer cell line with various responses to
oestrogens and antioestrogens. These clones were originally
derived simply by selecting cells that could grow in oestrogen-
free medium. The original cell population, T47D:C4, was
subsequently shown to be comprised of at least two distinct
subpopulations.
One group, exemplified by the T47D:C4:2W clone, has
permanently lost its ability to express ER and PR and no
longer responds to either oestrogens or antioestrogens.
Previous reports have described T47D cells with altered
hormone responsiveness, including the T47Dco cells, which
express low levels of ER and constitutively express PR
(Horwitz et al., 1982). The T47Dco cells have also been
shown to express mutant ER mRNAs. However, while these
RNAs code for proteins with altered activities, as assessed in
heterlogous systems, the mutant proteins have not been
detected in the T47Dco cells (Leslie et al., 1992). Subse-
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Figure 6 Growth response of T47D clones. Following growth
for 4 days in oestrogen-free medium, 15000 cells were seeded
into each well of a 24-well plate on day 0 and compounds were
added to triplicate wells the following day. Medium was changed
on day 4 and the cells harvested and DNA assays performed on
day 6. (a) Response of the clones to 17,B-oestradiol. b, Response
to 4-OHT. (c) Response to increasing concentrations of 4-OHT
in the presence of 0.1 nM 17fl-oestradiol. T47D:A18 (-E-),
T47D:C4:2W (-O-) and T47D:C4:5W (-A\).
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Figure 7 Activation of a luciferase reporter construct in T47D
clones. Cells were grown in oestrogen-free medium for 2 days
before being plated at 500000 cells per well in 6-well tissue culture
plates. T47D:A18 (-E1-), T47D:C4:2W (-A-) and T47D:C4:5W
(-O-) cells were then cotransfected with 1Ig of the luciferase
reporter construct, pVIT3-Luc, and 0.5ig of the constitutive f,-
galactosidase expression vector, pCMV,B. Compounds were then
added 6h later following a 3min glycerol shock. Cells were
extracted and luciferase activity measured 42h after compound
addition. All values are corrected for ,B-galactosidase activity as a
measure of relative transfection efficiency.
quently, other T47D clones have been described, which no
longer express measurable PR following selection by flow
cytometric sorting. However, the ER status of these T47D-Y
cells has not been reported (Sartorius et al., 1994).
The permanent loss of both ER and PR expression and
development of complete oestrogen and antioestrogen
sensitivity in vitro is a unique development and has not
been reported previously. In conjunction with the oestrogen-
responsive parental T47D:A18 clone, these cells will be a
unique model in which to study the specific changes
responsible for the loss of oestrogen-dependent growth.
Previous studies have used E2 responsive and non-responsive
cell lines with no common link other than their being
originally derived from breast cancers. The fact that the
T47D:A18 and T47D:C4:2W clone both come from a
common progenitor, as proven by DNA fingerprinting
analysis (Murphy et al., 1990), should allow the use of
techniques, such as differential display (Chen and Sager,
1995) and representational difference analysis (Lisitsyn et al.,
1993), to isolate gene products, which are either over-
expressed or repressed with the development of oestrogen
independence. The background differences inherent when
using cells from different sources will be eliminated in this
model system.
The expression of ER mRNA in the T47D:C4:2W clone,
as measured by PCR, is a provocative finding, but this
amount of ER mRNA appears to be functionally insignif-
icant. Using a variety of PCR conditions, we have
consistently observed specific ER PCR products in the
T47D:C4:2W and MDA-MB-231 cells at levels estimated
between 25% and 50% that observed in the T47D:A18 and
MCF-7 cells. The T47D:C4:2W cells have been maintained
for more than 2 years in oestrogen-containing medium and
continue to show no measurable responses to either
oestrogens or antioestrogens, as measured in Northern
blots, Western blots, 3H-E2 binding or induction of an
ER-sensitive luciferase reporter construct, suggesting that the
ER-negative phenotype is stable and not simply the result of
insufficient oestrogen exposure. Our results highlight the
potential of RT-PCR to generate products with no
Figure 8 Southern blot analysis of the ER gene in T47D clones.
Genomic DNA was prepared and 50,ug was digested with either
EcoRI or HindIII and run on a 0.8% agarose gel, transferred to
Hybond N and probed with a 32P-labelled human ER cDNA. A,
T47D:A18; B, T47D:C4:2W; C, T47D:C4:5W.
biological significance. This principle has been noted by
Pfeffer et al. (1995) with their description of numerous
mutations of the ER using RT-PCR in normal mammary
tissue, mammary tumour tissue and MCF-7 cells.
The second group, exemplified by the T47D:C4:5 clone,
expresses no measurable ER or PR and does not exhibit any
alterations in growth when exposed to oestrogen or
antioestrogens in short-term studies. However, when cul-
tured in the presence of oestrogens for extended times (>4
weeks), these cells begin to express measurable levels of ER
and PR mRNA and protein. The finding of a response to
oestrogens that can be blocked by antioestrogens suggests
that the T47D:C4:5 clone is not completely devoid of ER but
expresses it at such a low level as to be undetectable by any
method other than PCR. In contrast to the T47D:C4:2W
clone, the T47D:C4:5W clone demonstrates a slow accumula-
tion of functional ER protein, which can lead to the
reacquisition of oestrogen responses, such as growth
stimulation and transcription of oestrogen-responsive repor-
ter genes. This re-education of the T47D:C4:5 cells is a novel
observation, which has only recently been observed in cells
treated with 5-azacytidine (Ferguson et al., 1995).
The regulation of ER expression in T47D cells is quite
different from that observed in MCF-7 cells and the
development of oestrogen-independent clones in these cell
lines mirrors these differences (Pink and Jordan, 1996). The
oestrogen-independent clones that have been isolated from
MCF-7 cells, display a different phenotype from that
observed for the T47D clones. In short-term studies, MCF-
7 cells show increased expression of ER mRNA and protein
following removal of oestrogens and this increase can be
reversed by addition of oetrogens. However, MCF-7 cells,
which have adapted to growth in oestrogen-free medium for
more than 3 months, show a consistent but unusual
phenotype. They express high levels of ER and their growth
is inhibited by antioestrogens, but oestrogens cannot increase
their growth above basal levels. The addition of oestrogens to
the culture medium also causes an increase in PR mRNA and
protein, suggesting that the ER in these cells is still functional
(Katzenellenbogen et al., 1987; Welshons and Jordan, 1987).
We have previously isolated and characterised two oestrogen-
independent subclones in long-term studies. The MCF-7:5C
clone expresses wild-type ER but is completely oestrogen
independent and antioestrogen resistant (Jiang et al., 1992).
The second clone, MCF-7:2A, expresses a wild-type ER in
addition to a novel 80 kDa ER, which contains a duplication
of exons 6 and 7. The MCF-7:2A cells grow maximally in the
absence of oestrogens but their growth can be inhibited by
antioestrogens. These cells also display elevated expression of
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Figure 9 (a) SSCP analysis of ER cDNA in T47D clones. 1, MCF-7:WS8; 2, water control; 3, MDA-MB-231; 4, T47D:A18; 5,
T47D:C4:2W; 6, T47D:C4:5W. (b) Map of primer binding sites in the ER cDNA used in the SSCP analysis.
an oestrogen-responsive reporter plasmid in transient
transfection studies. Like growth, the basal luciferase
activity, mediated through the ER can be inhibited by
antioestrogens (Pink et al., 1995). This phenotype is very
similar to that observed in the initial studies of oestrogen
removal in MCF-7 cells. Whether the mutant ER is involved
in the regulation of growth in the MCF-7:2A cells is currently
unknown.
ER regulation is quite different in T47D cells because
oestrogen withdrawal causes a decrease in ER expression. It
is interesting to note that the regulation of ER expression in
short-term studies seems to be mirrored in the long-term
oestrogen withdrawal experiments. T47D clones, which are
oestrogen independent, show a loss or dramatic decrease in
ER expression, and MCF-7 clones, which are oestrogen
independent, all express relatively high levels of functional
ER. These examples serve to highlight the diversity of
pathways that can lead to the development of oestrogen-
independent growth.
Our studies on the effects of oestrogen withdrawal on the
T47D cell lines are especially relevant in the light of the
current clinical studies with the pure antioestrogen, ICI
182,780 (DeFriend et al., 1994; Howell et al., 1995).
Previously, the evaluation of ER expression in clinical
samples following the development of tamoxifen resistance
revealed a predominantly ER-positive population (Encarna-
cion et al., 1993). This is in contrast to the laboratory and
clinical observations following ICI 182,780 treatment, where-
by ER levels drop almost universally to undetectable levels
(DeFriend et al., 1994; Gibson et al., 1991). Mechanistically,
this would be analogous to complete oestrogen withdrawal,
which previously could not be achieved clinically. If the
clinical response to complete oestrogen withdrawal is similar
to that observed in the T47D clones described here, we would
hypothesise that the pure antioestrogens may give rise to a
higher proportion of ER-negative, completely hormonally
insensitive tumours. This is in contrast to MCF-7 tumours,
which show a different regulation of ER expression (Pink and
Jordan, 1996). MCF-7 cells show an increase in ER
expression following oestrogen deprivation. Depending upon
the type of regulation that is present in the individual tumour
observed clinically, the response to pure antioestrogen
treatment may vary dramatically. Our data suggest that
T47D-like tumours may show a rapid development of
oestrogen-independent growth. Treatment of these tumours
with a second-line antioestrogen would be futile. In contrast,
tumours that have become resistant to tamoxifen therapy
have been shown to respond to a second-line treatment with
ICI 182,780 (Howell et al., 1995; Osborne et al., 1995). This
suggests that the most efficacious treatment scheme would
employ tamoxifen initially, followed by the use of ICI
182,780 after disease recurrence.
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